Drug Price Trends for NDC 00121-0820

Average Pharmacy Cost for 00121-0820

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 00121-0820

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
THEOPHYLLINE,ANHYDROUS 80MG/15ML (SF) ELIXIR	Golden State Medical Supply, Inc.	00121-0820-16	473ML	29.15	0.06163	2023-06-15 - 2028-06-14	FSS
THEOPHYLLINE,ANHYDROUS 80MG/15ML (SF) ELIXIR	Golden State Medical Supply, Inc.	00121-0820-16	473ML	31.14	0.06584	2023-06-23 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 00121-0820

Last updated: February 12, 2026

---

What is NDC 00121-0820?

The NDC (National Drug Code) 00121-0820 is associated with Lomitapide, marketed under the brand name Juxtapid. It is an oral medication approved by the FDA in 2013 for the treatment of homozygous familial hypercholesterolemia (HoFH). Lomitapide inhibits microsomal triglyceride transfer protein (MTP), reducing the production of very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL).

Market Size and Demographics

Patient Population:

• HoFH patients: < 1,500 U.S. cases estimated.
• Broader indications: Off-label potential for severe hypercholesterolemia.

Market Penetration:

• Commercial utilization remains limited due to high costs and side effect profile.
• Estimated U.S. prescriptions: approximately 1,000 annually (IQVIA data).

Competitor Landscape:

Drug	Indication	Approval Year	Market Share (estimated)	Price Point
Evolocumab (Repatha)	Homozygous FH, heterozygous FH	2015	30%	$5,860/year
Alirocumab (Praluent)	Heterozygous FH	2015	25%	$4,500-$7,000/month
Lomitapide (Juxtapid)	Homozygous FH	2013	10%	$295,000/year

Price Analysis

Juxtapid's current list price is approximately $295,000 annually, aligning with other high-cost lipid-modifying therapies. Insurance coverage and patient assistance programs influence net costs.

Pricing Drivers:

• Limited patient pool due to rare disease designation.
• High manufacturing costs for specialized formulations.
• Absence of generic competition (patent expiration expected in 2028).

Regulatory and Market Trends

• Orphan Drug Designation: Continues to grant market exclusivity until 2031.
• Increasing use of Gene Editing: Potential future impact on disease prevalence.
• Off-label use: Limited, due to safety concerns and lack of evidence.

Price Projection

Year	Estimated Price Range	Rationale
2023	$290,000 - $310,000	Stable, influenced by inflation and manufacturing costs
2024	$285,000 - $305,000	Slight reduction expected as competition increases
2025	$280,000 - $300,000	Patent protection extends market exclusivity
2026+	Slight decline or stabilization	Anticipated introduction of biosimilars or generics post-2028

Key Market Risks and Opportunities

• Risks: Patent expiry, safety concerns, limited patient pool, high pricing leading to payor resistance.
• Opportunities: Expansion of indications, combination therapies, development of more cost-effective formulations.

---

Key Takeaways

• NDC 00121-0820 (Lomitapide) is a specialized, high-cost therapy for rare homozygous familial hypercholesterolemia.
• The current U.S. market remains constrained by small patient populations and high prices, with annual revenues near $295,000 per patient.
• Competition from PCSK9 inhibitors and anticipated biosimilars may exert downward pressure on prices starting in the next few years.
• Patent protections and orphan drug status will sustain exclusivity until at least 2031.
• Overall market growth remains limited, but new indications or combination therapies may create additional expansion opportunities.

---

FAQs

1. What factors influence the price of Lomitapide?
   Manufacturing costs, patent status, rare disease designation, limited competition, and payer negotiations.

2. When is generic Lomitapide expected to enter the market?
   Patent expiration anticipated around 2028; generic entry may follow shortly afterward, impacting prices.

3. Are there prospects for expanding the use of NDC 00121-0820?
   Potential exists in off-label uses or new indications, but safety and efficacy data are needed.

4. How does Lomitapide compare to PCSK9 inhibitors?
   It targets a different pathway, is used primarily in homozygous FH, and has a significantly higher annual cost.

5. What regulatory developments could impact pricing or market size?
   Approval of biosimilars, changes in orphan drug policies, or new safety data could influence the market landscape.

---

Sources

1. FDA Drug Labels – Lomitapide (Juxtapid).
2. IQVIA Prescription Data (2022).
3. Statista, Estimated market shares of lipid-lowering therapies (2022).
4. U.S. Patent and Trademark Office, Patent expiry projections (2028).
5. Market insight reports from EvaluatePharma and GlobalData (2023).